Ovarian dysfunction in mice following chromium (VI) exposure.
Chromium (VI) was given through drinking water in two sets of adult Swiss albino female mice in three doses; 250 ppm, 500 ppm and 750 ppm for 20 days in set 1 and 0.05 ppm, 0.5 ppm and 5.0 ppm in set II for 90 days. At the termination of the treatment, the animals of both the sets were euthanized for histopathology, follicle counting, counting of the superovulated ova, duration of estrus cycle and for ultrastructural studies. Ovaries of the highest dose group (750 ppm) showed large numbers of atretic follicles and congestion in stromal tissue compared to the rest of the treated groups. Also, there was a dose-dependent reduction in the number of follicles at different stages of their maturation. The number of ova recovered from superovulated chromium (VI)-treated animals showed significant decreases in the 500 and 750 ppm dosed groups compared to lower dosed (250 ppm) and control groups. The duration of estrus cycle increased in highest dosed (750 ppm) group. A dose-dependent increase in blood chromium level was also seen in treated mice. Ultrastructural observations revealed disintegrated cell membranes of two layered follicular cells and altered villiform mitochondria in thecal cells of 5 ppm dosed group. From the study it was concluded that ovarian physiology and rate of ovulation might be altered if females are exposed to sufficiently high chromium through oral route.
Murthy
R C
RC
Metal Analysis Laboratory, Industrial Toxicology Research Centre, Lucknow, India. intox@itrc.sirnetd.ernet.in
Junaid
M
M
Saxena
D K
DK
D000284:Administration, Oral; D000818:Animals; D002452:Cell Count / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000648:ultrastructure; D002840:Chromates / Q000008:administration & dosage / Q000633:toxicity*; D002857:Chromium / Q000097:blood; D004326:Drinking; D004971:Estrus / Q000187:drug effects*; D005260:Female; D051379:Mice; D008928:Mitochondria / Q000187:drug effects / Q000648:ultrastructure; D006080:Ovarian Follicle / Q000187:drug effects* / Q000648:ultrastructure; D010053:Ovary / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D017680:Potassium Compounds / Q000008:administration & dosage / Q000633:toxicity*
D002840:Chromates; D017680:Potassium Compounds; D002857:Chromium; C027373:potassium chromate(VI)